Loss of Interleukin-13-Receptor-Alpha-1 Induces Apoptosis and Promotes EMT in Pancreatic Cancer.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
26 Mar 2022
Historique:
received: 03 02 2022
revised: 24 03 2022
accepted: 25 03 2022
entrez: 12 4 2022
pubmed: 13 4 2022
medline: 14 4 2022
Statut: epublish

Résumé

In search of new therapies for pancreatic cancer, cytokine pathways have attracted increasing interest in recent years. Cytokines play a vital role in the crosstalk between tumour cells and the tumour microenvironment. The related inflammatory cytokines IL-4 and IL-13 can regularly be detected at increased levels in the microenvironment of pancreatic cancer. They share a receptor heterodimer consisting of IL-4Rα and IL-13Rα1. While IL-4Rα induces a more oncogenic phenotype, the role of IL-13Rα1 was yet to be determined. ShRNA-based knockdown of IL-13Rα1 was performed in Capan-1 and MIA PaCa-2. We assessed cell growth and migratory capacities under the influence of IL-13Rα1. Pathway alterations were detected by immunoblot analysis. We now have demonstrated that the loss of IL-13Rα1 induces apoptosis in pancreatic cancer cells. This was associated with an epithelial-to-mesenchymal transition. Loss of IL-13Rα1 also abolished the effects of exogenous IL-4 and IL-13 stimulation. Interestingly, in wild type cells, cytokine stimulation caused a similar increase in migratory capacities as after IL-13Rα1 knockdown. Overall, our results indicate the vital role of IL-13Rα1 in the progression of pancreatic cancer. The differential expression of IL-4Rα and IL-13Rα1 has to be taken into account when considering a cytokine-targeted therapy in pancreatic cancer.

Identifiants

pubmed: 35409019
pii: ijms23073659
doi: 10.3390/ijms23073659
pmc: PMC8998778
pii:
doi:

Substances chimiques

Cytokines 0
IL13RA1 protein, human 0
Interleukin-13 0
Interleukin-13 Receptor alpha1 Subunit 0
Interleukin-4 207137-56-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : China Scholarship Council
ID : 201806090357

Références

J Immunol. 2019 Nov 1;203(9):2532-2544
pubmed: 31548328
Cancer Discov. 2019 Feb;9(2):282-301
pubmed: 30366930
Cent Eur J Immunol. 2019;44(2):190-200
pubmed: 31530989
Int J Mol Sci. 2020 Oct 03;21(19):
pubmed: 33022971
Oncogene. 2014 Jun 19;33(25):3256-66
pubmed: 23912451
Cancer Res. 2002 Jul 1;62(13):3575-80
pubmed: 12097255
Biomed Khim. 2019 Aug;65(5):424-431
pubmed: 31666416
J Hematol Oncol. 2019 Feb 26;12(1):20
pubmed: 30808369
Genes Dev. 1999 Nov 15;13(22):2905-27
pubmed: 10579998
Sci Signal. 2015 Nov 10;8(402):ra114
pubmed: 26554818
Annu Rev Immunol. 1999;17:701-38
pubmed: 10358772
Sci Rep. 2019 Feb 27;9(1):2924
pubmed: 30814616
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Int J Colorectal Dis. 2009 Jan;24(1):57-67
pubmed: 18758789
Cancer Discov. 2020 Apr;10(4):608-625
pubmed: 32046984
Oncol Rep. 2020 Aug;44(2):637-649
pubmed: 32467989
Front Immunol. 2019 Nov 13;10:2638
pubmed: 31798581
Int J Mol Sci. 2017 Mar 28;18(4):
pubmed: 28350325
Int Rev Immunol. 1998;17(1-4):1-52
pubmed: 9914942
Semin Cancer Biol. 2021 Nov;76:232-246
pubmed: 34062264
Cytokine. 2015 Sep;75(1):68-78
pubmed: 26070934
Immunity. 2019 Apr 16;50(4):832-850
pubmed: 30995502
Br J Cancer. 2005 Mar 14;92(5):921-8
pubmed: 15714203
J Cancer. 2017 Feb 25;8(5):761-773
pubmed: 28382138
Neuro Oncol. 2010 Aug;12(8):871-81
pubmed: 20511192
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Oncogene. 2008 Oct 6;27(45):5904-12
pubmed: 18836471
Cancer Lett. 2020 Feb 1;470:126-133
pubmed: 31730903
Cancer Discov. 2020 Oct;10(10):1566-1589
pubmed: 32703770
Oncotarget. 2016 Sep 20;7(38):61183-61198
pubmed: 27533463
J Radiat Res. 2020 May 22;61(3):376-387
pubmed: 32100006
J Clin Oncol. 2015 Dec 1;33(34):4039-47
pubmed: 26351344
Cancer Res. 2012 Dec 15;72(24):6338-43
pubmed: 23222300
Breast Cancer Res. 2003;5(1):31-6
pubmed: 12559043
Cell Signal. 2002 May;14(5):381-95
pubmed: 11882383
Acta Biomater. 2020 Jan 1;101:43-68
pubmed: 31518706
Anticancer Res. 1999 Jan-Feb;19(1A):125-31
pubmed: 10226533
Expert Rev Clin Immunol. 2017 May;13(5):425-437
pubmed: 28277826
J Allergy Clin Immunol. 2020 Aug;146(2):367-376.e3
pubmed: 32407835
Genome Med. 2016 May 03;8(1):38
pubmed: 27137215
Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):333-348
pubmed: 29717230
Cancer Immunol Immunother. 2017 Nov;66(11):1485-1496
pubmed: 28733709
Acta Microbiol Immunol Hung. 2015 Dec;62(4):341-78
pubmed: 26689873
Drug Saf. 2018 May;41(5):489-509
pubmed: 29411337
Int J Mol Sci. 2021 Mar 15;22(6):
pubmed: 33804263
Oncotarget. 2017 Aug 3;8(48):83370-83383
pubmed: 29137350

Auteurs

Jingwei Shi (J)

Department of General and Visceral Surgery, Ulm Univsersity Hospital, Albert-Einstein-Allee 23, 89081 Ulm, Germany.

Xiao Shen (X)

Department of General and Visceral Surgery, Ulm Univsersity Hospital, Albert-Einstein-Allee 23, 89081 Ulm, Germany.

Qi Kang (Q)

Department of General and Visceral Surgery, Ulm Univsersity Hospital, Albert-Einstein-Allee 23, 89081 Ulm, Germany.

Xing Yang (X)

Department of General and Visceral Surgery, Ulm Univsersity Hospital, Albert-Einstein-Allee 23, 89081 Ulm, Germany.

Maximilian Denzinger (M)

Department of General and Visceral Surgery, Ulm Univsersity Hospital, Albert-Einstein-Allee 23, 89081 Ulm, Germany.

Marko Kornmann (M)

Department of General and Visceral Surgery, Ulm Univsersity Hospital, Albert-Einstein-Allee 23, 89081 Ulm, Germany.

Benno Traub (B)

Department of General and Visceral Surgery, Ulm Univsersity Hospital, Albert-Einstein-Allee 23, 89081 Ulm, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH